Literature DB >> 16734846

Retroperitoneoscopic pre-transplant native kidney nephrectomy.

Rajiv Goel1, Pranjal Modi, Sharad Dodia.   

Abstract

AIMS: Laparoscopic nephrectomy has become a standardized procedure for removal of benign non-functioning kidneys. We present our experience of retroperitoneoscopic pre-transplant native kidneys nephrectomy.
METHODS: Comparison of 40 patients who underwent retroperitoneoscopy with 40 open simple pre-transplant nephrectomy patients was done.
RESULTS: Forty retroperitoneoscopic nephrectomies were done between June 2003 and April 2005. The mean operative time was similar in the two groups; however, the mean blood loss, postoperative analgesic requirement, complication rate, hospital stay and convalescence period were significantly less in the retroperitoneoscopic group.
CONCLUSION: Retroperitoneoscopic nephrectomy should be offered as the primary treatment modality to patients requiring pre-transplant native kidney nephrectomy, except in patients where it is contraindicated.

Entities:  

Mesh:

Year:  2006        PMID: 16734846     DOI: 10.1111/j.1442-2042.2006.01311.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

1.  Laparoscopic nephrectomy in patients undergoing hemodialysis treatment.

Authors:  Oner Sanli; Tzevat Tefik; Mazhar Ortac; Meltem Karadeniz; Tayfun Oktar; Ismet Nane; Murat Tunc
Journal:  JSLS       Date:  2010 Oct-Dec       Impact factor: 2.172

2.  Retroperitoneoscopic nephrectomy for benign nonfunctioning kidneys: Training and outcome.

Authors:  Yusuf Saifee; Ramya Nagarajan; Syed Javed Qadri; Amlan Sarmah; Suresh Kumar; Bipin Chandra Pal; Pranjal Modi
Journal:  Indian J Urol       Date:  2016 Oct-Dec

3.  Pertinent issues in pretransplant recipient workup.

Authors:  Pranjal Modi
Journal:  Indian J Urol       Date:  2007-07

4.  Simultaneous bilateral native nephrectomy by retroperitoneal approach.

Authors:  Piotr Jarzemski; Sławomir Listopadzki; Piotr Słupski; Marcin Jarzemski; Bartosz Brzoszczyk
Journal:  Int Braz J Urol       Date:  2020 Jul-Aug       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.